Authors

University of North Carolina, Lineberger Comprehensive Cancer Center

Latest:

Phase 1b Study of Azacitidine, Venetoclax and Revumenib in Newly Diagnosed Older Adults with NPM1 Mutated or KMT2A Rearranged AML: Interim Results of Dose Escalation from the Beat AML Consortium

A Phase 1b study (NCT03013998) to determine the safety and recommended dose of Revumenib combined with Aza/Ven in patients with newly diagnosed AML ≥ 60 years old with NPM1mut or KMT2Ar and who are not candidates or do not wish to pursue intensive induction therapy.

Rohan Garje, MD

Latest:

Dr Garje on Unmet Needs in Small Cell Bladder Cancer

Rohan Garje, MD, discusses the unmet needs for patients with small cell bladder cancer.

Gwendolyn M. Bryant-Smith, MD

Latest:

Comprehensive Treatment Advances Care for Patients With Early-Stage Breast Cancer

Advances in the diagnosis and treatment of early-stage breast cancer highlight the need for clinicians to adapt to paradigm shifts that will have notable effects on patient care.

Samuel U. Takvorian, MD, MS

Latest:

Dr Takvorian on the Evolution of PARP Inhibitors in Prostate Cancer

Samuel U. Takvorian, MD, MS, discusses the evolution of regulatory decisions regarding the use of PARP inhibitors for patients with prostate cancer.

Reema A. Patel, MD

Latest:

Dr. Patel on a Subgroup Analysis of the NAPOLI-1 Trial in Pancreatic Cancer

Reema A. Patel, MD, discusses the results of a subgroup analysis from the NAPOLI-1 trial in pancreatic cancer.

Joseph Maakaron, MD

Latest:

Dr Maakaron on Choosing Between Bispecific Antibodies and CAR T-Cell Therapy in DLBCL

Joseph Maakaron, MD, discusses factors that influence his decision to use bispecific antibodies or CAR T-cell therapy in patients with DLBCL.

Karl Semaan, MD, MSc

Latest:

Dr Semaan on Liquid Biopsy vs Tissue Biopsy for Detecting Sarcomatoid RCC

Karl Semaan, MD, MSc, discusses the clinical advantages of liquid biopsy over tissue biopsies in detecting sarcomatoid renal cell carcinoma.

Neal Navani, MRCP, MSc, PhD, University College London Hospitals NHS Foundation Trust

Latest:

EGFR+ NSCLC: Advice for Community Oncologists

A panel of experts in thoracic oncology concludes the discussion by emphasizing the importance of conducting reflex molecular testing, considering systemic therapy in all patients, and utilizing shared decision-making models.

Enrique Grande, MD, PhD, Msc

Latest:

Cabozantinib plus Atezolizumab in Locally Advanced/Metastatic Adrenocortical Carcinoma: Results From a Multi-Cohort Basket Phase II Trial (CABATEN/GETNE-T1914)

Enrique Grande, MD, PhD, Msc, presents the results of a multi-cohort basket phase II trial, CABATEN/GETNE-T1914, evaluating cabozantinib plus atezolizumab in patients with locally advanced/metastatic adrenocortical carcinoma.

Eno-Abasi Inyang, PharmD, BCPS, BCOP

Latest:

Monitoring and Follow-Up of Patients with Chronic GVHD

The panel closes by reviewing the patient case once more and shares clinical pearls on the treatment of patients with GVHD.

Warren S. Brenner, MD

Latest:

Dr. Brenner on the Role of Trastuzumab Deruxtecan in Gastric Cancer

Warren S. Brenner, MD, discusses the utilization of fam-trastuzumab deruxtecan-nxki (Enhertu) as a HER2-directed therapy in gastric cancer.

Ciara Freeman, MD, PhD

Latest:

Dr Freeman on Factors Influencing Response to CAR T-Cell Therapy in Hematology